Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody
Open Access
- 1 January 2004
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 279 (4), 2856-2865
- https://doi.org/10.1074/jbc.m310132200
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasiaSeminars in Oncology, 2002
- The EGFR family and its ligands in human cancerEuropean Journal Of Cancer, 2001
- The IGF-I Receptor in Cancer ResearchExperimental Cell Research, 1999
- Novel tetravalent and bispecific IgG‐like antibody molecules combining single‐chain diabodies with the immunoglobulin γ1 Fc or CH3 regionFEBS Letters, 1999
- An efficient route to human bispecific IgGNature Biotechnology, 1998
- Design and production of novel tetravalent bispecific antibodiesNature Biotechnology, 1997
- The Insulin-Like Growth Factor-I Receptor Signaling Pathways Are Important for Tumorigenesis and Inhibition of ApoptosisCritical Reviews™ in Oncogenesis, 1997
- Monoclonal antibody αIR-3 inhibits non-small cell lung cancer growth in vitro and in vivoJournal of Cellular Biochemistry, 1996
- Toward the Production of Bispecific Antibody Fragments for Clinical ApplicationsJournal of Hematotherapy, 1995
- Engineering high affinity humanized anti‐p185HER2/anti‐CD3 bispecific F(ab′)2 for efficient lysis of p185HER2 overexpressing tumor cellsInternational Journal of Cancer, 1995